Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1373-1380

  Shi, Zhi ^a   Jain, Sandeep ^c   Kim, In Wha ^d   Peng, Xing Xiang ^a   Abraham, Ioana ^a   Youssef, Diaa T A ^e   Fu, Li Wu ^b   El Sayed, Khalid ^a,c   Ambudkar, Suresh V ^d   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Suez Canal University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; COLCHICINE; CYTOTOXIC AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; SIPHOLENOL A; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; MARINE ENVIRONMENT; MEMBRANE VESICLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; AZIDES; CALLYSPONGIA; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IODINE RADIOISOTOPES; KB CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; PRAZOSIN; TRITERPENES;

EID: 34547815196     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00554.x     Document Type: Article

References (37)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
2. Ambudkar SV, Dey S, Hrycyna CA et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
3. Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992; 43: 2601-8.
4. Germann UA, Shlyakhter D, Mason VS et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997; 8: 125-40.
5. van Zuylen L, Sparreboom A, van der Gaast A et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000; 6: 1365-71.
6. Newman MJ, Rodarte JC, Benbatoul KD et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000; 60: 2964-72.
7. Dantzig AH, Shepard RL, Cao J et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-9.
8. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-602.
9. Roe M, Folkes A, Ashworth P et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 1999; 9: 595-600.
10. Daenen S, van der Holt B, Verhoef GE et al. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. Leuk Res 2004; 28: 1057-67.
11. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia. Cancer Leukemia Group B Study 9720. Blood 2002; 100: 1224-32.
12. Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002; 38: 418-26.
13. Fu L, Liang Y, Deng L et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 2004; 53: 349-56.
14. Chen LM, Wu XP, Ruan JW et al. Screening novel, potent multidrug-resistant modulators from imidazole derivatives. Oncol Res 2004; 14: 355-62.
15. Chen LM, Liang YJ, Ruan JW et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 2004; 56: 1061-6.
16. Nagayama S, Chen ZS, Kitazono M et al. Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Lett 1998; 130: 175-82.
17. Okumura H, Chen ZS, Sakou M et al. Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. Mol Pharmacol 2000; 58: 1563-9.
18. Aoki S, Chen ZS, Higasiyama K et al. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. Jpn J Cancer Res 2001; 92: 886-95.
19. Shi Z, Liang YJ, Chen ZS et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006; 5: 39-47.
20. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. Marine natural products as anticancer drugs. Mol Cancer Ther 2005; 4: 333-42.
21. Jain SLS, Shi Z, Fu LW et al. Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. J Nat Prod 2007; 70: 928-31.
22. Cornwell MM, Gottesman MM, Pastan IH. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 1986; 261: 7921-8.
23. Ramachandra M, Ambudkar SV, Chen D et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 1998; 37: 5010-19.
24. Kerr KM, Sauna ZE, Ambudkar SV. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem 2001; 276: 8657-64.
25. Shi Z, Liang YJ, Chen ZS et al. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncol Rep 2007; 17: 969-76.
26. Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Meth Enzymol 1998; 292: 504-14.
27. Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci USA 2000; 97: 2515-20.
28. Chen ZS, Aoki S, Komatsu M et al. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer 2001; 93: 107-13.
29. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60: 47-50.
30. Mitsuo M, Noguchi T, Nakajima Y et al. Binding site(s) on P-glycoprotein for a newly synthesized photoaffinity analog of agosterol A. Oncol Res 2003; 14: 39-48.
31. Ren XQ, Furukawa T, Aoki S et al. A positively charged amino acid proximal to the C-terminus of TM17 of MRP1 is indispensable for GSH-dependent binding of substrates and for transport of LTC4. Biochemistry 2002; 41: 14 132-40.
32. Isenberg B, Thole H, Tummler B, Demmer A. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. Eur J Biochem 2001; 268: 2629-34.
33. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-85.
34. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610-17.
35. Carson SW, Ousmanou AD, Hoyler SL. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology. Psychopharmacol Bull 2002; 36: 67-81.
36. Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006; 27: 392-400.
37. Martin C, Berridge G, Higgins CF et al. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000; 58: 624-32.